This page is updated frequently with new Receptor-related patent applications.
| Methods and compositions for diagnosis and prognosis of renal injury and renal failure|
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of heat shock 70 kda protein 1, alpha-1-antitrypsin neutrophil elastase complex, stromelysin-1:metalloproteinase inhibitor 2 complex, 72 kda type iv collagenase:metalloproteinase inhibitor 2 complex, insulin-like growth factor 1 receptor, myeloid differentiation primary response protein myd88, neuronal cell adhesion molecule, and tumor necrosis factor ligand superfamily member 10 as diagnostic and prognostic biomarkers in renal injuries..
Astute Medical, Inc.
| Method for detecting cardiovascular disease biomarker|
A method for analyzing concentration of a cardiovascular disease (cvd) biomarker in a liquid sample includes: applying the liquid sample to a biosensor, the biosensor including a transistor having a drain, a source, and a gate terminal disposed between the gate and the source, and a reactive electrode spaced apart from the gate terminal of the transistor and having a receptor immobilized thereon for specific binding with the cvd biomarker, the liquid sample being in contact with the gate terminal and the reactive electrode; applying a voltage pulse between the reactive electrode and the source, the voltage pulse having a pulse width; monitoring a response current in response to the voltage pulse; and analyzing the response current.. .
National Tsing Hua University
| Molecular sensor preparations and uses thereof|
The present invention relates to a method of preparing a molecular sensor that is specific for a target molecule having a saccharide or peptide region. The method comprises using the target molecule as a template and incubating the template with a receptor to form a template-receptor complex.
The University Of Birmingham
| Localized surface plasmon resonance sensing of human performance biomarkers using short peptide recognition elements on optically active metal nanostructures|
A biomarker sensor using short peptide recognition elements. The biomarker sensor includes a substrate and a metallic layer on a surface of that substrate that is localized surface plasmon resonance reactive.
Government Of The United States As Represented By The Secretary Of The Air Force
| Novel estrogen receptor mutations and uses thereof|
Novel mutant esr1 molecules and uses are disclosed.. .
Foundation Medicine, Inc.
| Method for generating t-cells compatible for allogenic transplantation|
The present invention pertains to engineered t-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered t-cells of the invention are characterized in that the expression of beta 2-microglobulin (b2m) and/or class ii major histocompatibility complex transactivator (ciita) is inhibited, e.g., by using rare-cutting endonucleases able to selectively inactivating by dna cleavage the gene encoding b2m and/or ciita, or by using nucleic acid molecules which inhibit the expression of b2m and/or ciita.
| Compositions and methods for treating cachexia|
The present invention relates, in various embodiments, to methods of treating cachexia (e.g., cancer cachexia) in a patient. The methods comprise administering at least one compound for inhibiting, in alternative embodiments, the expression or activity of a microrna that is present in microvesicles secreted from cancer cells in the patient (e.g., a mir-21 gene product), the expression or activity of a toll-like receptor (e.g., tlr7, tlr8), the expression or activity of a c-jun n-terminal kinase (jnk), the secretion of microvesicles from cancer cells, or the fusion of microvesicles from cancer cells with muscle cells or adipocytes.
| Multivalent and multispecific dr5-binding fusion proteins|
The disclosure relates generally to molecules that specifically engage death receptor 5 (dr5), a member of the tnf receptor superfamily (tnfrsf). More specifically the disclosure relates to multivalent and multispecific molecules that bind at least dr5..
| Human antigen binding proteins that bind betta-klotho, fgf receptors and complexes thereof|
The present invention provides compositions and methods relating to or derived from antigen binding proteins activate fgf21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-klotho; (ii) fgfr1c, fgfr2c, fgfr3c or fgfr4; or (iii) a complex comprising β-klotho and one of fgfr1c, fgfr2c, fgfr3c, and fgfr4.
| Insulin-like growth factor 1 receptor -specific antibodies and uses thereof|
The blood-brain barrier (bbb) prevents transport of molecules larger than 500 daltons from blood to brain. receptor-mediated transcytosis (rmt) facilitates transport across the bbb of specific molecules that bind receptors on brain endothelial cells that form the bbb.
National Research Council Of Canada
Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
The blood-brain barrier (bbb) prevents transport of molecules larger than 500 dal tons from blood to brain. receptor-mediated transcytosis (rmt) facilitates transport across the bbb of specific molecules that bind receptors on brain endothelial cells that form the bbb.
National Research Council Of Canada
Defined composition gene modified t-cell products
Aspects of the invention described herein, concern approaches to make genetically modified t-cells comprising a chimeric antigen receptor for human therapy. In some alternatives, the methods utilize a selection and/or isolation of cd4+ and/or cd8+ t-cells from a mixed t-cell population, such as, peripheral blood or apheresis derived mononuclear cells.
Seattle Children's Hospital (dba Seattle Children's Research Institute)
Production of cytotoxic antibody-toxin fusion in eukaryotic algae
Methods and compositions are disclosed to engineer chloroplast comprising heterologous genes encoding target binding domain fused to a eukaryotic toxin and produced within a subcellular organelle, such as a chloroplast. The present disclosure demonstrates that when chloroplasts are used, toxins normally refractive to production in eukaryotic cells may be used to produce recombinant fusion proteins with binding domains that are soluble, properly folded and post-translationally modified, where the multifunctional activity of the fusion protein is intact.
Binding proteins against vegf, pdgf, and/or their receptors
Binding proteins that bind one or more of vegf, pdgf and/or their receptors, including antibodies, cdr-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins..
Novel substitution mutant receptors and their use in an ecdysone receptor-based inducible gene expression system
This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression.
Methods for engineering t-cell receptors
The present invention provides a method for engineering a t-cell receptor domain polypeptide comprising at least one modification in a structural loop region of the t-cell receptor domain polypeptide and determining the binding of the t-cell receptor domain polypeptide to an epitope of an antigen, wherein the unmodified t-cell receptor domain polypeptide does not significantly bind to the epitope. The present invention also covers modified t cell receptor domain polypeptides, their use and libraries containing the modified t cell receptor domain polypeptides..
F-star Biotechnologische Forschungs- Und Entwicklungsges.m.b.h
Growth hormone receptor agonists
We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone related diseases that would benefit from growth hormone agonists or antagonists.. .
Chemokine-immunoglobulin fusion polypeptides, compositions, making and use thereof
This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival..
Jyant Technologies, Inc.
Claudin-6-specific immunoreceptors and t cell epitopes
The present invention provides claudin-6-specific immunoreceptors (t cell receptors and artificial t cell receptors (chimeric antigen receptors; cars)) and t cell epitopes which are useful for immunotherapy.. .
Ganymed Pharmceuticals Ag
Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
The present invention relates to compositions and methods for preparing splice variants of tnfalpha receptor (tnfr) in vivo or in vitro, and the resulting tnfr protein variants. Such variants may be prepared by controlling the splicing of pre-mrna molecules and regulating protein expression with splice switching oligonucleotides or splice switching oligomers (ssos).
Roche Innovation Center Copenhagen A/s
Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors
Pyrrolo[2,3-d]pyrimidine derivatives, and pharmaceutical acceptable salts thereof, useful in therapeutically treating patients with cancer are disclosed. These compounds selectively target folate receptors (fr) of cancerous tumor cells and inhibit purine synthesis and hence, dna synthesis..
Wayne State University
Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
Methods and compositions for treating cancers such as pancreatic cancer and synovial sarcoma are disclosed. Compounds comprising a sigma-2 receptor-binding moiety and a ferroptosis-inducing moiety are described.
Compound having selective ep2 agonist activity
A compound represented by general formula (i) wherein all symbols are as defined in the specification, a salt or n-oxide of the compound, or a solvate or prodrug of the compound or the salt or n-oxide has a selective ep2 agonist activity and is highly safe, and is therefore useful as a drug, especially as a therapeutic agent for ep2 receptor-related diseases including immune diseases, allergic diseases, neuronal death, dysmenorrhea, premature birth, miscarriage, baldness, ocular diseases, erectile dysfunction, arthritis, lung injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, bone diseases, cartilage injury and others.. .
Ono Pharmaceutical Co., Ltd.
Substituted 2-azabicycles and their use as orexin receptor modulators
Wherein x is n or cr1; y is n or cr2; r1 is h, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; r2 is h, alkyl, alkoxy, or halo; z is nh or o; r3 is h, alkyl, alkoxy, halo, or triazolyl; r4 is h or alkyl; or r3 and r4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring; r5 is pyridyl, pyrazinyl, or pyrimidinyl, wherein the pyridyl, pyrazinyl, or pyrimidinyl is optionally substituted with halo or alkyl; and n is 1 or 2. Methods of making the compounds of formula i are also described.
Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
This invention relates to compounds that are agonists of the muscarinic m1 receptor and/or m4 receptor and which are useful in the treatment of muscarinic m1/m4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.
Heptares Therapeutics Limited
Use of arylalkanolamines as sigma-1 receptor antagonists
The present invention relates to the use of arylalkanolamine compounds with sigma-1 receptor antagonist activity. In particular, the said arylalkanolamine compounds are useful in the treatment of conditions selected from the abuse of psychotropic substances such as cocaine or amphetamines, pain and cancer..
Università Degli Studi Di Pavia
Tin-117m somatostatin receptor binding compounds and methods
Tin-117m somatostatin analogues or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic.
Pharmaceutical compositions for high-capacity targeted delivery
Provided herein are aptamers and pharmaceutical compositions comprising the same. In some embodiments, the aptamer selectively binds a protein of interest such as an extracellular receptor protein of interest (e.g., a cancer cell extracellular receptor protein, which may be differentially expressed in some embodiments).
Wake Forest University Health Sciences
Chimeric antigen receptor (car) signalling system
The present invention relates to a chimeric antigen receptor (car) signalling system comprising; (i) a receptor component comprising an extracellular antigen-binding domain, a transmembrane domain and a intracellular first chemical inducer of dimerization binding domain 1 (cbd1); and (ii) an intracellular signalling component comprising a signalling domain and a second chemical inducer of dimerization binding domain 2 (cbd2); wherein cbd1 and cbd2 are capable of simultaneously binding to a chemical inducer of dimerization (cid); wherein, in the absence of the cid, binding of the antigen-binding component to antigen does not result in signalling through the signalling component; whilst, in the presence of the cid, the receptor component and the signalling component heterodimerize and binding of the antigen-binding domain to antigen results in signalling through the signalling domain.. .
Ucl Business Plc
Prostate cancer vaccine
Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer.
Wisconsin Alumni Research Foundation
Long-acting peptide analogs
Long-acting agonistic analogs for clr/ramp receptors are provided that have an extended half-live in vivo.. .
The Board Of Trustees Of The Leland Stanford Junior University
Compositions and methods for treating peritoneal cancers
The present disclosure provides compositions and methods for treating a peritoneal cancer in a subject. The methods include administering a t cell which is genetically modified to express a chimeric t cell receptor protein.
Prospect Chartercare Rwmc, Llc D/b/a Roger Williams Medical Center
Compositions and methods of treating t cell mediated disorder
A method of generating a cd4+foxp3+ treg cell, the method includes administering at least one complement antagonist to a naive cd4+ t cell at an amount effective to substantially inhibits c3a receptor (c3ar) and/or c5a receptor (c5ar) signal transduction in the cd4+ t cell, induce tgf-β1 expression of the cd4+ t cell, and induce differentiation of the of the naive cd4+ t cell into a cd4+foxp3+ treg cell.. .
Case Western Reserve University
Induction of thyroid iodide-handling gene expression in human cancers
Dual suppression of the map kinase and pi3k/akt pathways showed synergistic or greatly enhanced anti-melanoma cell effects, compared to suppression of a single pathway, including the inhibition of cell proliferation, transformation and invasion, induction of g0/g1 cell cycle arrest and, importantly, cell apoptosis. Remarkably, suppression of either pathway induces the expression of thyroid iodide-handling genes and dual suppression of the two pathways synergistically and robustly induces expression of these genes, accompanied by uptake of radioiodine in the cells.
The Johns Hopkins University
Use of thiopyrimidinecarboxamide for treating cancer
Alone or in combination with an antineoplastic agent, microtubule affecting agents, antineoplastic agents, anti-angiogenesis agents, vegf receptor kinase inhibitors, antibodies against the vegf receptor, interferon, or radiation.. .
Use of nk-1 receptor antagonists for treating hypomagnesemia, neurogenic inflammation, and cardiac dysfunction associated with egfr-blocking drugs
The present disclosure provides methods for alleviating or preventing the negative physiological side effects associated with the administration of egfr blocking therapeutics. The disclosure provides, inter alia, methods for treating or preventing: hypomagnesemia, cardiac dysfunction, and skin lesions, which are induced by egfr blocking drugs, by administering an nk-1 receptor antagonist..
The George Washington University
Medicament for suppressing malignant tumor metastasis
Provided are a novel medicament for suppressing or preventing the metastasis of a malignant tumor such as carcinoma, a novel treatment or prevention method for suppressing or preventing the metastasis of a malignant tumor, etc. The medicament comprises a non-peptidic angiotensin type 2 receptor agonist as an active ingredient.
Mitsubishi Tanabe Pharma Corporation
Nuclear receptor binding agents
The present application relates to methods of treating, preventing, delaying the onset of, reducing the incidence of, or reducing the severity of fibrosis, obesity and conditions associated with post-menopausal obesity.. .
Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Described herein, inter alia, are compounds useful for the prevention or treatment of hyperproliferative diseases or disorders.. .
The Regents Of The University Of California
Sgk1 inhibitors for treatment of prostate cancer
The present invention encompasses the recognition that reproducible and detectable changes in the level and or activity of sgk1 are associated with incidence and/or risk of castration resistant prostate cancer (crpc) and/or doubly resistant prostate cancer, specifically in individuals having prostate cancer and on antiandrogen therapy, and provides for the use of sgk1 inhibitors to treat and/or reduce risk of crpc and/or doubly resistant prostate cancer. In some embodiments, sgk1 inhibitors also have glucocorticoid receptor (gr) and/or androgen receptor (ar) inhibitory activity or are administered in conjunction with gr and/or ar inhibitors..
Sloan-kettering Institute For Cancer Research
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
The present invention relates to certain pyrazole derivatives of formula (i) and pharmaceutical compositions thereof that modulate the activity of the 5-ht2a serotonin receptor and their uses for the treatment and prophylaxis of visual hallucinations associated with lewy body dementia.. .
Axovant Sciences Ltd.
New somatostatin receptor subtype 4 (sstr4) agonists
3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (sstr4), useful for preventing or treating medical disorders related to sstr4.. .
Centrexion Therapeutics Corporation
Cannabinoid receptor treatments
The present invention includes methods and compositions for treating a transplant recipient by administration of a cb2 receptor agonist either alone or in combination with one or more active pharmaceutical ingredients to block the rejection of foreign tissue and prolong grafted organs, tissues and cells.. .
Image forming apparatus
In one embodiment, an image forming apparatus has a mirror which reflects an optical scanning beam toward a photoreceptor, so as to expose the photoreceptor. The image forming apparatus further has a rotating cam and a stopper.
Toshiba Tec Kabushiki Kaisha
Diagnosis of cancer by detecting auto-antibodies against epidermal growth factor (egf)
The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against epidermal growth factor (egf) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an epidermal growth factor receptor inhibitor..
Diagnosis of cancer by detecting auto-antibodies against egf-receptor
The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against epidermal growth factor receptor (egfr) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an inhibitor of egfr activity..
Shon as a prognostic biomarker for cancer and as a predictor of response to endocrine therapy
An estrogen-regulated gene sequence shon has been characterised, and found to be a novel oncogene in mammary carcinoma and significantly associated with estrogen and progesterone receptor expression in breast cancer. The present invention encompasses methods for predicting the responsiveness to endocrine therapy for breast cancer and providing a prognosis for disease-free and/or distant metastasis-free survival of a cancer patient..
Membrane phase electrode using printing and bio-molecule detection using same
A membrane electrode includes a novel sensor combining a filtering function of a membrane and a signal measuring ability of an electrode. A target material may be measured by filtration through the membrane.
Korea Research Institute Of Bioscience And Biotechnology